Phase II evaluation of sunitinib in the treatment of recurrent or refractory high‐grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021

Sunitinib malate is a small multi‐targeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR), platelet‐derived growth factor receptor (PDGFR) and stem cell factor receptor (KIT), which are highly expressed by some high‐grade brain tumors. We conducted a phas...

Descripción completa

Detalles Bibliográficos
Autores principales: Wetmore, Cynthia, Daryani, Vinay M., Billups, Catherine A., Boyett, James M., Leary, Sarah, Tanos, Rachel, Goldsmith, Kelly C., Stewart, Clinton F., Blaney, Susan M., Gajjar, Amar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944867/
https://www.ncbi.nlm.nih.gov/pubmed/27109549
http://dx.doi.org/10.1002/cam4.713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944867/
https://www.ncbi.nlm.nih.gov/pubmed/27109549
http://dx.doi.org/10.1002/cam4.713

Ejemplares similares